<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2020-01-02">
  <drugbank-id primary="true">DB06261</drugbank-id>
  <name>Hexaminolevulinate</name>
  <description>Hexaminolevulinate is an optical imaging drug. In solution form it is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy. On May 28, 2010, the U.S. Food and Drug Administration (FDA) granted approval for hexaminolevulinate hydrochloride (Cysview for Intravesical Solution, Photocure ASA), as an optical imaging agent for use in combination with the Karl Storz Photodynamic Diagnostic D-Light C (PDD) System for cystoscopic detection of non-muscle invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Hexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®.</description>
  <cas-number>140898-97-1</cas-number>
  <unii>G7H20TKI67</unii>
  <average-mass>215.293</average-mass>
  <monoisotopic-mass>215.15214354</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A4129</ref-id>
        <pubmed-id>24248555</pubmed-id>
        <citation>Yang LP: Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. Mol Diagn Ther. 2014 Feb;18(1):105-16. doi: 10.1007/s40291-013-0068-x.</citation>
      </article>
      <article>
        <ref-id>A4130</ref-id>
        <pubmed-id>21068759</pubmed-id>
        <citation>O'Brien T, Thomas K: Bladder cancer: Photodynamic diagnosis can improve surgical outcome. Nat Rev Urol. 2010 Nov;7(11):598-9. doi: 10.1038/nrurol.2010.183.</citation>
      </article>
      <article>
        <ref-id>A4131</ref-id>
        <pubmed-id>18177838</pubmed-id>
        <citation>Hillemanns P, Wang X, Hertel H, Andikyan V, Hillemanns M, Stepp H, Soergel P: Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2008 Mar;198(3):300.e1-7. doi: 10.1016/j.ajog.2007.07.045. Epub 2008 Feb 21.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Hexaminolevulinate is indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. </indication>
  <pharmacodynamics>In vitro studies have shown increased porphyrin fluorescence in normal urothelium after exposure to hexaminolevulinate hydrochloride intravesical solution. In the human bladder, a greater accumulation of porphyrins is proposed in neoplastic or inflamed cells, compared to normal urothelium. After bladder instillation of hexaminolevulinate hydrochloride intravesical solution for approximately 1 hour and subsequent illumination with blue light at wavelengths 360 – 450nm, the porphyrins will fluoresce red.</pharmacodynamics>
  <mechanism-of-action>Hexaminolevulinate is an ester of the heme precursor, aminolevulinic acid. After bladder instillation, hexaminolevulinate enters the bladder mucosa and is proposed to enter the intracellular space of mucosal cells where it is used as a precursor in the formation of the photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins (PAPs). PpIX and PAPs are reported to accumulate preferentially in neoplastic cells as compared to normal urothelium, partly due to altered enzymatic activity in the neoplastic cells. After excitation with light at wavelengths between 360 and 450 nm, PpIX and other PAPs return to a lower energy level by fluorescing, which can be detected and used for cystoscopic detection of lesions. The fluorescence from tumor tissue appears bright red and demarcated, whereas the background normal tissue appears dark blue. Similar processes may occur in inflamed cells.</mechanism-of-action>
  <toxicity>No studies in animals have been conducted to evaluate the carcinogenic potential of hexaminolevulinate hydrochloride. &#13;
&#13;
Hexaminolevulinate hydrochloride was not mutagenic in in-vitro reverse mutation tests in bacteria, or in chromosome aberration tests in human peripheral blood lymphocytes, and was negative in an in-vivo micronucleus test in mice after intravenous injection of doses up to 45 mg/kg in the absence of light activation.&#13;
&#13;
Adequate studies have not been performed to evaluate the genetic toxicity of hexaminolevulinate hydrochloride in the presence of light activation. &#13;
&#13;
Adequate reproductive and developmental toxicity studies in animals have not been performed to evaluate the effects of hexaminolevulinate hydrochloride on fertility. </toxicity>
  <metabolism>Rapid metabolism in human blood.</metabolism>
  <absorption>Absolute bioavailability 7% (90% confidence interval [CI]: 5%-10%)</absorption>
  <half-life>Biphasic elimination, with an initial elimination half-life of 39 minutes, followed by a terminal half-life of approximately 76 hours.</half-life>
  <protein-binding>No evidence of significant binding.</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as delta amino acids and derivatives. These are compounds containing a carboxylic acid group and an amino group at the C5 carbon atom.</description>
    <direct-parent>Delta amino acids and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>Alpha-amino ketones</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Fatty acid esters</alternative-parent>
    <alternative-parent>Gamma-keto acids and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alpha-aminoketone</substituent>
    <substituent>Amine</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Delta amino acid or derivatives</substituent>
    <substituent>Fatty acid ester</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Gamma-keto acid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Keto acid</substituent>
    <substituent>Ketone</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001174</drugbank-id>
      <name>Hexaminolevulinate hydrochloride</name>
      <unii>D4F329SL1O</unii>
      <cas-number>140898-91-5</cas-number>
      <inchikey>LZYXPFZBAZTOCH-UHFFFAOYSA-N</inchikey>
      <average-mass>251.75</average-mass>
      <monoisotopic-mass>251.1288213</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="iupac">4-Hexyloxycarbonyl-2-oxobutylammoniumchloride</synonym>
    <synonym language="spanish" coder="">Hexaminolevulinato</synonym>
    <synonym language="english" coder="usan">Hexyl 5-amino-4-oxopentanoate hydrochloride</synonym>
    <synonym language="german" coder="inn">Hexyl(5-amino-4-oxopentanoat)-hydrochlorid</synonym>
    <synonym language="english" coder="usan">Pentanoic acid, 5-amino-4-oxo-, hexyl ester, hydrochloride</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cysview</name>
      <labeller>Biosyent Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02436639</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravesical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cysview</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>0407-4086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-01</started-marketing-on>
      <ended-marketing-on>2011-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>100 mg/50mL</strength>
      <route>Intravesical</route>
      <fda-application-number>NDA022555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cysview</name>
      <labeller>Photocure Asa</labeller>
      <ndc-id/>
      <ndc-product-code>10511-3001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength>100 mg/50mL</strength>
      <route>Intravesical</route>
      <fda-application-number>NDA022555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Hexvix</name>
      <company>GE Healthcare</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Cysview</name>
      <ingredients>Hexaminolevulinate</ingredients>
    </mixture>
    <mixture>
      <name>Cysview</name>
      <ingredients>Hexaminolevulinate</ingredients>
    </mixture>
    <mixture>
      <name>Cysview</name>
      <ingredients>Hexaminolevulinate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids</category>
      <mesh-id>D000596</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Carbon Radioisotopes</category>
      <mesh-id>D002250</mesh-id>
    </category>
    <category>
      <category>Keto Acids</category>
      <mesh-id>D007651</mesh-id>
    </category>
    <category>
      <category>Levulinic Acids</category>
      <mesh-id>D007982</mesh-id>
    </category>
    <category>
      <category>Other Diagnostics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Photosensitizing Agents</category>
      <mesh-id>D017319</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form/>
      <route>Intravesical</route>
      <strength>100 mg/50mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravesical</route>
      <strength>100 mg/50mL</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravesical</route>
      <strength>100 mg</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>36:89.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06261.pdf?1455587228</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06261.pdf?1455587228</msds>
  <patents>
    <patent>
      <number>6034267</number>
      <country>United States</country>
      <approved>2000-03-07</approved>
      <expires>2016-03-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7247655</number>
      <country>United States</country>
      <approved>2007-07-24</approved>
      <expires>2016-03-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7530461</number>
      <country>United States</country>
      <approved>2009-05-12</approved>
      <expires>2017-01-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7348361</number>
      <country>United States</country>
      <approved>2008-03-25</approved>
      <expires>2020-11-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00707</drugbank-id>
      <name>Porfimer sodium</name>
      <description>Hexaminolevulinate may increase the photosensitizing activities of Porfimer sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00460</drugbank-id>
      <name>Verteporfin</name>
      <description>Hexaminolevulinate may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>BCG vaccine may decrease effectiveness of Hexaminolevulinate as a diagnostic agent.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.55</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.11e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>hexyl 5-amino-4-oxopentanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>hexyl 5-amino-4-oxopentanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>215.293</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>215.15214354</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H]N([H])CC(=O)CCC(=O)OCCCCCC</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C11H21NO3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RYQOILLJDKPETL-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>69.39</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>58.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>24.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>16.11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>7.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22564</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>134892</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6433083</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310264865</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04436</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4938272</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cysview</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201784</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cysview-drug/clinical-pharmacology.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/international/hexaminolevulinate-hydrochloride.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>